Structures by: Kandri Rodi Y. O.
Total: 74
6-Bromo-2-(4-chlorophenyl)-3-[(1-octyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C23H26BrClN6
IUCrData (2019) 4, 1 x190053
a=16.252(3)Å b=5.3787(9)Å c=27.109(4)Å
α=90° β=90.551(12)° γ=90°
7-Bromo-1,4-bis(prop-2-ynyl)pyrido[2,3-<i>b</i>]pyrazine-2,3(1<i>H</i>,4<i>H</i>)-dione
C13H8BrN3O2
IUCrData (2018) 3, 2 x180266
a=10.1922(5)Å b=17.3470(10)Å c=7.0216(4)Å
α=90° β=92.382(5)° γ=90°
(Pyridin-2-yl)methyl 6-bromo-2-oxo-1-[(pyridin-2-yl)methyl]-1,2-dihydroquinoline-4-carboxylate
C22H16BrN3O3
IUCrData (2018) 3, 2 x180288
a=34.0146(11)Å b=4.9522(2)Å c=23.4539(7)Å
α=90° β=111.5780(10)° γ=90°
1-Benzyl-5-bromoindoline-2,3-dione
C15H10BrNO2
IUCrData (2016) 1, 4 x160559
a=4.52050(10)Å b=13.4538(3)Å c=21.0436(5)Å
α=90° β=90° γ=90°
1,1'-(Hexane-1,6-diyl)bis(indoline-2,3-dione)
C22H20N2O4
IUCrData (2016) 1, 4 x160542
a=15.1498(3)Å b=7.4949(2)Å c=16.4795(3)Å
α=90° β=90° γ=90°
1-[(2<i>E</i>)-3-Phenylprop-2-en-1-yl]-1<i>H</i>-indole-2,3-dione
C17H13NO2
IUCrData (2016) 1, 4 x160633
a=8.2585(2)Å b=7.26770(10)Å c=44.4667(8)Å
α=90° β=90° γ=90°
1-Propyl-1<i>H</i>-indole-2,3-dione
C11H11NO2
IUCrData (2016) 1, 4 x160609
a=4.4666(2)Å b=12.9169(6)Å c=16.3857(8)Å
α=90° β=90° γ=90°
5-Fluoro-1-(prop-2-en-1-yl)-2,3-dihydro-1<i>H</i>-indole-2,3-dione
C11H8FNO2
IUCrData (2017) 2, 1 x170028
a=31.531(3)Å b=4.2752(4)Å c=14.1080(13)Å
α=90° β=90° γ=90°
5-Bromo-1-octylindoline-2,3-dione
C16H20BrNO2
IUCrData (2016) 1, 3 x160371
a=4.5284(2)Å b=13.2044(6)Å c=25.9133(11)Å
α=96.663(3)° β=90.728(3)° γ=95.393(3)°
6-Bromo-2-methyl-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C7H6BrN3
IUCrData (2016) 1, 5 x160766
a=11.0395(12)Å b=6.4734(7)Å c=11.1397(12)Å
α=90° β=98.8890(10)° γ=90°
6-Bromo-2-(4-chlorophenyl)-3-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C13H9BrClN3
IUCrData (2016) 1, 5 x160763
a=12.1163(2)Å b=9.7911(2)Å c=20.9428(4)Å
α=90° β=90° γ=90°
Ethyl 2-(6-bromo-2-phenyl-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-1-yl)acetate
C16H14BrN3O2
IUCrData (2016) 1, 5 x160771
a=14.6923(8)Å b=6.1988(3)Å c=16.2254(8)Å
α=90° β=92.9110(10)° γ=90°
1-Allyl-5-chloroindoline-2,3-dione
C11H8ClNO2
IUCrData (2016) 1, 6 x160862
a=31.2222(6)Å b=7.9107(2)Å c=8.3373(2)Å
α=90° β=90° γ=90°
5-Bromo-1-(6-bromohexyl)indoline-2,3-dione
C14H15Br2NO2
IUCrData (2016) 1, 6 x160883
a=4.6344(2)Å b=12.6284(6)Å c=25.3537(12)Å
α=90° β=90° γ=90°
1-Benzyl-5-chloroindoline-2,3-dione
C15H10ClNO2
IUCrData (2016) 1, 6 x160854
a=4.4576(2)Å b=27.6646(11)Å c=20.9530(8)Å
α=90° β=93.870(2)° γ=90°
5-Chloro-1-methylindoline-2,3-dione
C9H6ClNO2
IUCrData (2016) 1, 6 x160913
a=3.9766(4)Å b=11.9503(13)Å c=17.947(2)Å
α=90° β=96.163(3)° γ=90°
6-Chloro-1,4-diethylquinoxaline-2,3(1<i>H</i>,4<i>H</i>)-dione
C12H13ClN2O2
IUCrData (2017) 2, 7 x171052
a=14.6454(8)Å b=12.0415(5)Å c=15.1149(9)Å
α=90° β=115.621(7)° γ=90°
5-Methyl-4-(3-methyl-1-phenyl-1<i>H</i>-pyrazol-4-yl)-2-phenyl-2,3-dihydro-1<i>H</i>-pyrazol-3-one
C20H18N4O
IUCrData (2017) 2, 6 x170853
a=18.2838(13)Å b=7.7956(6)Å c=11.8081(8)Å
α=90° β=100.393(3)° γ=90°
5-Fluoro-1-[(1-{[(1<i>S</i>,2<i>R</i>,6<i>R</i>,8<i>S</i>,9<i>R</i>)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0^2,6^]dodecan-8-yl]methyl}-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-2,3-dihydro-1<i>H</i>-indole-2,3-dione
C23H25FN4O7
IUCrData (2017) 2, 5 x170739
a=11.1688(2)Å b=9.0576(2)Å c=11.9237(2)Å
α=90° β=106.7700(10)° γ=90°
1,4-Dibenzyl-6-chloroquinoxaline-2,3(1<i>H</i>,4<i>H</i>)-dione
C22H17ClN2O2
IUCrData (2017) 2, 6 x170901
a=29.2234(4)Å b=8.3076(2)Å c=31.0407(5)Å
α=90° β=101.859(2)° γ=90°
6-Bromo-2-(4-methoxyphenyl)-3-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C14H12BrN3O
IUCrData (2017) 2, 7 x171071
a=14.8643(6)Å b=7.6795(4)Å c=12.0690(5)Å
α=90° β=108.465(4)° γ=90°
(Pyridin-2-yl)methyl 2-oxo-1-[(pyridin-2-yl)methyl]-1,2-dihydroquinoline-4-carboxylate hemihydrate
C22H17N3O3,0.5(H2O)
IUCrData (2017) 2, 7 x171038
a=4.96340(10)Å b=14.0708(3)Å c=25.7168(6)Å
α=90° β=90.6020(10)° γ=90°
7-Bromo-1,4-dibutyl-1,2,3,4-tetrahydropyrido[2,3-<i>b</i>]pyrazine-2,3-dione
C15H20BrN3O2
IUCrData (2017) 2, 7 x170984
a=22.569(6)Å b=5.1097(13)Å c=13.497(3)Å
α=90° β=90° γ=90°
1-[(1-Benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-1<i>H</i>-1,3-benzodiazole
C17H15N5
IUCrData (2017) 2, 6 x170944
a=5.34830(10)Å b=14.1861(4)Å c=19.1408(5)Å
α=90° β=97.4510(10)° γ=90°
Prop-2-ynyl 2-oxo-1-(prop-2-ynyl)-1,2-dihydroquinoline-4-carboxylate
C16H11NO3
IUCrData (2017) 2, 7 x171072
a=7.3070(11)Å b=8.7763(13)Å c=11.2927(13)Å
α=91.059(11)° β=107.867(12)° γ=109.814(14)°
Ethyl 1-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
C13H13NO3
IUCrData (2017) 2, 6 x170917
a=12.2269(4)Å b=6.7034(3)Å c=14.0817(5)Å
α=90° β=90° γ=90°
4-Benzyl-6-bromo-2-(4-chlorophenyl)-4<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C19H13BrClN3
IUCrData (2017) 2, 6 x170899
a=8.7749(7)Å b=9.9403(7)Å c=10.4475(8)Å
α=76.030(6)° β=66.511(7)° γ=85.843(6)°
1-[(1-{[(1<i>S</i>,2<i>R</i>,6<i>R</i>,8<i>R</i>,9<i>S</i>)-4,4,11,11-Tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0^2,6^]dodecan-8-yl]methyl}-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-2,3-dihydro-1<i>H</i>-indole-2,3-dione
C23H26N4O7
IUCrData (2017) 2, 5 x170670
a=25.6622(8)Å b=8.7731(3)Å c=10.3928(3)Å
α=90° β=101.8470(10)° γ=90°
2-Oxo-1,2-dihydroquinoline-4-carboxylic acid monohydrate
C10H7NO3,H2O
IUCrData (2016) 1, 6 x160997
a=20.7884(8)Å b=3.72150(10)Å c=23.8849(9)Å
α=90° β=98.582(2)° γ=90°
1-(12-Bromododecyl)-5-chloroindoline-2,3-dione
C20H27BrClNO2
IUCrData (2016) 1, 6 x160971
a=8.0353(4)Å b=8.3496(5)Å c=17.1096(11)Å
α=84.491(3)° β=78.086(3)° γ=65.126(2)°
7-Bromo-2,3-bis[(prop-2-yn-1-yl)sulfanyl]pyrido[2,3-<i>b</i>]pyrazine
C13H8BrN3S2
IUCrData (2016) 1, 11 x161881
a=4.21590(10)Å b=16.7730(5)Å c=19.4656(5)Å
α=90° β=91.1490(10)° γ=90°
Ethyl 2-{6-bromo-2-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-3-yl}acetate
C16H14BrN3O2
IUCrData (2016) 1, 12 x161999
a=21.1444(14)Å b=7.6970(5)Å c=21.2671(14)Å
α=90° β=118.0730(10)° γ=90°
1-(3-Bromopropyl)indoline-2,3-dione
C11H10BrNO2
IUCrData (2016) 1, 4 x160593
a=7.7113(2)Å b=8.1375(2)Å c=17.8089(4)Å
α=90° β=93.8300(13)° γ=90°
1,4-Dibenzyl-6-methyl-1,4-dihydroquinoxaline-2,3-dione
C23H20N2O2
Acta Crystallographica Section E (2020) 76, 8 1361-1364
a=9.0844(12)Å b=18.7227(18)Å c=11.2708(14)Å
α=90° β=104.848(4)° γ=90°
6-Bromo-3-(12-bromododecyl)-2-(4-nitrophenyl)-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C24H30Br2N4O2
Acta Crystallographica Section E (2020) 76, 5 677-682
a=6.3291(11)Å b=9.8911(17)Å c=21.133(4)Å
α=76.480(2)° β=84.965(3)° γ=73.891(2)°
Ethyl 2-{4-[(2-ethoxy-2-oxoethyl)(phenyl)carbamoyl]-2-oxo-1,2-\ dihydroquinolin-1-yl}acetate
C24H24N2O6
Acta Crystallographica Section E (2019) 75, 11 1753-1758
a=16.9368(5)Å b=15.4130(4)Å c=18.4562(6)Å
α=90° β=109.254(4)° γ=90°
4-Allyl-6-bromo-2-(4-chlorophenyl)-4<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C15H11BrClN3
Acta Crystallographica Section E (2019) 75, 1 43-48
a=7.6218(5)Å b=8.5238(5)Å c=11.1093(7)Å
α=95.739(3)° β=98.880(3)° γ=94.979(3)°
5,5-Diphenyl-1,3-bis(prop-2-yn-1-yl)imidazolidine-2,4-dione
C21H16N2O2
Acta Crystallographica Section E (2019) 75, 7 951-956
a=10.144(3)Å b=7.952(2)Å c=10.928(3)Å
α=90° β=97.104(12)° γ=90°
2-Chloroethyl 2-oxo-1-(prop-2-yn-1-yl)-1,2-dihydroquinoline-4-carboxylate
C15H12ClNO3
Acta Crystallographica Section E (2019) 75, 10 1411-1417
a=7.1809(2)Å b=21.4466(5)Å c=8.9173(2)Å
α=90° β=92.784(2)° γ=90°
5-Bromo-1-{2-[2-(2-chloroethoxy)ethoxy]ethyl}indoline-2,3-dione
C14H15BrClNO4
Acta Crystallographica Section E (2019) 75, 9 1372-1378
a=12.4682(4)Å b=14.6397(5)Å c=8.3524(3)Å
α=90° β=91.392(2)° γ=90°
5-Chloro-1,3-bis[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C17H19ClN4O5
Acta Crystallographica Section E (2015) 71, 10 o735-o736
a=14.053(8)Å b=13.438(6)Å c=9.733(4)Å
α=90° β=90° γ=90°
Ethyl {4-[(1,5-dimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1<i>H</i>-1,5- benzodiazepin-3-yl)methyl]-1,2,3-triazol-1-yl}acetate
C18H21N5O4
Acta Crystallographica Section E (2010) 66, 11 o3039
a=8.5452(2)Å b=15.9993(5)Å c=13.9215(4)Å
α=90.00° β=106.8530(10)° γ=90.00°
3-[(1-Benzyl-1<i>H</i>-1,2,3-triazol-5-yl)methyl]-6-bromo-2-phenyl- 3<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C22H17BrN6
Acta Crystallographica Section E (2011) 67, 4 o890-o891
a=41.122(6)Å b=5.8358(10)Å c=15.988(3)Å
α=90° β=93.922(6)° γ=90°
5-Nitro-1-nonyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C16H23N3O3
Acta Crystallographica Section E (2011) 67, 3 o669
a=5.4830(10)Å b=10.2092(15)Å c=14.746(3)Å
α=74.275(9)° β=79.727(6)° γ=83.410(8)°
1-Nonyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C16H24N2O
Acta Crystallographica Section E (2011) 67, 2 o283
a=18.0230(10)Å b=5.4585(2)Å c=16.5708(9)Å
α=90.00° β=115.543(7)° γ=90.00°
1,3-Bis[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]-1<i>H</i>-benzimidazol- 2(3<i>H</i>)-one
C17H20N4O5
Acta Crystallographica Section E (2011) 67, 2 o362-o363
a=10.5331(10)Å b=10.9647(10)Å c=14.5541(14)Å
α=90° β=103.258(5)° γ=90°
1,5-Dimethyl-3-[(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)methyl]- 1<i>H</i>-1,5-benzodiazepine-2,4(3<i>H</i>,5<i>H</i>)-dione
C21H21N3O3
Acta Crystallographica Section E (2010) 66, 11 o2983
a=9.3491(2)Å b=6.97220(10)Å c=27.9201(5)Å
α=90.00° β=93.1570(10)° γ=90.00°
7-Chloro-1,5-dipropargyl-1<i>H</i>-1,5-benzodiazepine- 2,4(3<i>H</i>,5<i>H</i>)-dione
C15H11ClN2O2
Acta Crystallographica Section E (2010) 66, 12 o3228
a=10.7755(3)Å b=7.6580(2)Å c=16.7221(5)Å
α=90.00° β=103.6210(10)° γ=90.00°
1,3-Dibenzyl-1<i>H</i>-anthra[1,2-<i>d</i>]imidazole-2,6,11(3<i>H</i>)-trione
C29H20N2O3
Acta Crystallographica Section E (2011) 67, 5 o1253-o1254
a=8.1389(3)Å b=12.8748(4)Å c=21.5528(8)Å
α=90.00° β=90.00° γ=90.00°
1,3-Bis(prop-2-ynyl)-1<i>H</i>-1,3-benzimidazol-2(3<i>H</i>)-one
C13H10N2O
Acta Crystallographica Section E (2011) 67, 5 o1091
a=7.7398(4)Å b=17.1869(9)Å c=8.4856(5)Å
α=90.00° β=101.459(6)° γ=90.00°
1-Decyl-6-nitro-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C17H25N3O3
Acta Crystallographica Section E (2011) 67, 11 o2937
a=32.9827(6)Å b=4.55881(9)Å c=29.3435(5)Å
α=90.00° β=109.481(2)° γ=90.00°
3-Allyl-6-bromo-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C9H8BrN3O
Acta Crystallographica Section E (2011) 67, 8 o1998
a=4.5138(5)Å b=9.7750(9)Å c=11.5717(11)Å
α=78.748(2)° β=82.526(3)° γ=86.038(2)°
1-Acetyl-6-bromo-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C8H6BrN3O2
Acta Crystallographica Section E (2011) 67, 6 o1375
a=4.8302(15)Å b=9.645(3)Å c=9.809(3)Å
α=81.542(7)° β=85.735(7)° γ=89.676(8)°
Ethyl 8-amino-6-bromoimidazo[1,2-<i>a</i>]pyridine-2-carboxylate
C10H10BrN3O2
Acta Crystallographica Section E (2011) 67, 6 o1390
a=8.366(2)Å b=11.842(3)Å c=22.743(5)Å
α=90.00° β=98.328(6)° γ=90.00°
5-Nitro-1,3-bis(prop-2-ynyl)-1<i>H</i>-1,3-benzimidazol-2(3<i>H</i>)-one
C13H9N3O3
Acta Crystallographica Section E (2013) 69, 7 o1159
a=20.0988(16)Å b=4.2645(3)Å c=28.669(2)Å
α=90° β=90° γ=90°
1-Allyl-3-benzyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C17H16N2O
Acta Crystallographica Section E (2013) 69, 9 o1477-o1478
a=9.0667(2)Å b=9.3922(2)Å c=9.6486(2)Å
α=94.2180(10)° β=113.5430(10)° γ=106.2650(10)°
1-Octylindoline-2,3-dione
C16H21NO2
Acta Crystallographica Section E (2013) 69, 12 o1801
a=20.266(4)Å b=4.69250(10)Å c=15.7807(11)Å
α=90.00° β=108.941(18)° γ=90.00°
1-Octyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C15H22N2O
Acta Crystallographica Section E (2012) 68, 5 o1276
a=14.8888(18)Å b=5.8395(6)Å c=16.6778(19)Å
α=90.00° β=91.448(3)° γ=90.00°
1-(Prop-2-ynyl)-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C10H8N2O
Acta Crystallographica Section E (2013) 69, 1 o119
a=4.5553(6)Å b=18.001(3)Å c=10.7488(13)Å
α=90.00° β=93.645(8)° γ=90.00°
1-(4-Methylbenzyl)-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C15H14N2O
Acta Crystallographica Section E (2013) 69, 1 o122
a=12.5585(5)Å b=5.7181(2)Å c=17.4153(7)Å
α=90.00° β=95.277(2)° γ=90.00°
1,3-Diallyl-6-bromo-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C12H12BrN3O
Acta Crystallographica Section E (2011) 67, 8 o1986
a=5.4110(3)Å b=25.4205(12)Å c=9.3170(4)Å
α=90.00° β=90.00° γ=90.00°
6-Bromoimidazo[1,2-<i>a</i>]pyridin-8-amine
C7H6BrN3
Acta Crystallographica Section E (2011) 67, 11 o2838
a=15.1378(5)Å b=21.2006(8)Å c=6.9744(3)Å
α=90.00° β=92.6106(7)° γ=90.00°
1,3-Dibenzyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C21H18N2O
Acta Crystallographica Section E (2011) 67, 12 o3234
a=19.5983(7)Å b=9.0882(2)Å c=10.0473(3)Å
α=90.00° β=115.593(4)° γ=90.00°
5-Chloro-1-nonyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C16H23ClN2O
Acta Crystallographica Section E (2011) 67, 12 o3340-o3341
a=5.51441(17)Å b=15.6507(4)Å c=20.0540(6)Å
α=71.807(3)° β=86.612(2)° γ=80.709(2)°
5-Nitro-1-(prop-2-yn-1-yl)-2,3-dihydro-1<i>H</i>-1,3-benzodiazol-2-one
C10H7N3O3
Acta Crystallographica Section E (2012) 68, 4 o1240
a=7.2541(2)Å b=10.0362(2)Å c=14.6793(3)Å
α=100.9780(10)° β=92.0470(10)° γ=109.0430(10)°
1-Allyl-1<i>H</i>-1,3-benzimidazol-2(3<i>H</i>)-one
C10H10N2O
Acta Crystallographica Section E (2012) 68, 11 o3212
a=10.2749(5)Å b=5.5787(3)Å c=16.6220(9)Å
α=90.00° β=100.976(4)° γ=90.00°
1-Dodecyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2(3<i>H</i>)-one
C19H30N2O
Acta Crystallographica Section E (2012) 68, 11 o3069
a=38.3223(14)Å b=4.8318(2)Å c=21.9831(8)Å
α=90.00° β=117.843(2)° γ=90.00°
1-Allyl-5-nitro-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C10H9N3O3
Acta Crystallographica Section E (2013) 69, 3 o431
a=8.3246(3)Å b=14.9567(6)Å c=16.4461(7)Å
α=90.00° β=90.00° γ=90.00°
1-[(1-Benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]indoline-2,3-dione
C18H14N4O2
Acta Crystallographica Section E (2014) 70, 5 o588
a=11.53860(18)Å b=5.38700(9)Å c=23.2433(4)Å
α=90.00° β=92.1048(16)° γ=90.00°
Ethyl 2-oxo-3-(3-phthalimidopropyl)-2,3-dihydro-1<i>H</i>-1,3-benzimidazole-1-carboxylate
C21H19N3O5
Acta Crystallographica Section E (2013) 69, 5 o641-o642
a=5.2850(7)Å b=10.6663(12)Å c=16.505(2)Å
α=86.454(7)° β=83.424(8)° γ=89.376(7)°
3-Benzyl-6-bromo-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C13H10BrN3O
Acta Crystallographica Section E (2013) 69, 6 o962
a=4.2399(2)Å b=10.4463(4)Å c=14.5144(6)Å
α=107.611(2)° β=90.628(3)° γ=99.784(3)°
6-Bromo-1,3-bis[(1,3-dioxolan-2-yl)methyl]-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C14H16BrN3O5
Acta Crystallographica Section E (2013) 69, 7 o1029-o1030
a=5.11440(10)Å b=17.8029(4)Å c=16.5365(5)Å
α=90.00° β=97.009(2)° γ=90.00°
3-Benzyl-1-{[3-(4-chlorophenyl)isoxazol-5-yl]methyl}-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C24H18ClN3O2
Acta Crystallographica Section E (2013) 69, 9 o1451
a=8.5427(2)Å b=9.8290(2)Å c=13.2658(3)Å
α=81.1330(10)° β=78.7630(10)° γ=64.3430(10)°
3-(2,3-Dioxoindolin-1-yl)propanenitrile
C11H8N2O2
Acta Crystallographica Section E (2014) 70, 3 o361-o362
a=7.1967(2)Å b=9.9909(3)Å c=13.5534(5)Å
α=77.508(3)° β=81.551(3)° γ=77.717(3)°